ArticleMolecular and cellular biochemistry2009
Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression.
Article in Molecular and cellular biochemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications.Endocrine-related cancer · 2023Review
- Evening Primrose (Antioxidants (Basel, Switzerland) · 2018Review
- Intracellular IL-37b interacts with Smad3 to suppress multiple signaling pathways and the metastatic phenotype of tumor cells.Oncogene · 2017Article
- Evidence of histidine and aspartic acid phosphorylation in human prostate cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2015Article
- Regulation of the metastasis suppressor Nm23-H1 by tumor viruses.Naunyn-Schmiedeberg's archives of pharmacology · 2015Review
- Metastasis suppressor genes.Histology and histopathology · 2013Review
- Genomics screens for metastasis genes.Cancer metastasis reviews · 2012Review
- Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.British journal of cancer · 2012Article
- Expression patterns of ER, HER2, and NM23-H1 in breast cancer patients with different menopausal status: correlations with metastasis.Molecular diagnosis & therapy · 2011Article
- Rethinking the metastatic cascade as a therapeutic target.Nature reviews. Clinical oncology · 2011Review
- Regulation of Nm23-H1 and cell invasiveness by Kaposi's sarcoma-associated herpesvirus.Journal of virology · 2011Article
- Mass spectrometric characterization of protein structure details refines the proteome signature for invasive ductal breast carcinoma.Journal of the American Society for Mass Spectrometry · 2011Article
- Mass spectrometry detection of histidine phosphorylation on NM23-H1.Journal of proteome research · 2011Article
- Metastasis suppressor genes at the interface between the environment and tumor cell growth.International review of cell and molecular biology · 2011Review
- Nucleoside diphosphate kinase (NDPK, NM23, AWD): recent regulatory advances in endocytosis, metastasis, psoriasis, insulin release, fetal erythroid lineage and heart failure; translational medicine exemplified.Molecular and cellular biochemistry · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Interruption of the tumor metastatic process is a new, thought provoking molecular target for the treatment of cancer. The Nm23-H1 metastasis suppressor gene stands as a validated molecular target owing to its reduced expression in many aggressive human tumors, and the reduction in metastatic potential in vivo upon re-expression in multiple cell lines. Several compounds have been identified which elevate Nm23-H1 expression in vitro including indomethacin, gamma Linolenic Acid, trichostatin A, 5-aza-deoxycytidine, and high dose medroxyprogesterone acetate. Using a model of lung metastatic colonization by MDA-MB-231 human breast carcinoma cells, we demonstrated that high dose MPA reduced the formation of overt lung metastases by 37-46% and those metastases that formed were statistically smaller. A Phase II clinical trial of high dose MPA, alone or in combination with metronomic chemotherapy has recently opened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.